We love Kim and we thank her for her good work, one of Kim's role at SSH incudes clinical trial risk management , that one has not gone too well, is Kim's work now complete ? was Kim just on loan from Medtronic to get SSH and the FDA up to speed with the interim analysis and trial enrollments up and set FDA guidelines for CP2 ? be very interesting to get some answers , good luck investors.
kim olesson leaves position head of clinical affairs, page-2
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)